Navigation Links
Women Taking Certain Epilepsy Drugs Can Safely Breast-Feed, Study Suggests
Date:11/24/2010

By Madonna Behen
HealthDay Reporter

WEDNESDAY, Nov. 24 (HealthDay News) -- There's encouraging news for women with epilepsy who want to nurse their babies. Children whose mothers took certain anti-seizure medications while breast-feeding don't appear to suffer any negative cognitive effects by age 3, a new study finds.

The multi-center study looked at nearly 200 children whose mothers took one of four common antiepileptic drugs, and found no difference in IQ levels at age 3 among those who were breast-fed versus formula-fed.

"For women who have epilepsy, this is one less thing that they as new mothers have to worry about," said lead author Dr. Kimford Meador, a professor of neurology at Emory University in Atlanta. The study was published in the Nov. 24 online edition and in the Nov. 30 print issue of the journal Neurology.

The findings are part of the Neurodevelopmental Effects of Antiepileptic Drugs study, an ongoing trial looking at the long-term cognitive effects on children whose mothers took one of four common antiepilepsy meds during and after their pregnancies: carbamazepine (Carbatrol, Equetro, Tegretol, Tegretol XR), lamotrigine (Lamictal), phenytoin (Dilantin, Phenytek) or valproate (Depakote, Depakote ER, Depakene).

For the study, Meador and his colleagues examined the results of IQ tests given to 199 three-year-olds whose mothers entered the trial while they were still pregnant. A total of 194 women at 25 epilepsy centers were enrolled in the study from 1999 to 2004, and there were five sets of twins.

Forty-two percent of the babies were breast-fed, for an average of six months, and mothers who breast-fed tended to have higher average IQs than those who didn't (104 versus 95). After controlling for the mother's IQ, the researchers found that the average IQ in the breast-fed group of children was 99, versus 98 in the non-breast-fed group.

The new study on breast-feeding comes after other research suggesting hazards to the developing fetus from exposure to one anti-seizure medication. Last year, the researchers reported that babies who were exposed to the drug valproate in utero had IQs at age 3 that were an average of 9 points lower than babies whose mothers took one of the other three drugs during pregnancy. They also found that the effect was dose-dependant, meaning the higher the dose of valproate, the lower the IQ. Other studies have shown that exposure to valproate during the first trimester can increase the risk of birth defects.

Meador speculated that one reason there was no difference in IQ levels among breast-fed and formula-fed babies exposed to valproate may be because "the level of the drug in the infants' bloodstreams was very much lower than it was during pregnancy."

Dr. Autumn Klein is director of the Program in Women's Neurology at Brigham and Women's Hospital in Boston, and the author of an editorial accompanying the study. She said the study "provides the most information thus far" when it comes to counseling women who take antiepilepsy drugs on the risks of breast-feeding.

Klein believes the findings "will definitely change" people's attitudes toward the use of these drugs during breast-feeding. Right now, she said, many doctors do not recommend breast-feeding for women taking the medications "due to the largely unknown effects of [antiepilepsy drugs] during breast-feeding."

Dr. Jacqueline French, a professor of neurology at New York University School of Medicine who treats many women with epilepsy, said the findings were reassuring in that, "even if a drug produces problems in utero, it doesn't produce additional problems for the baby during breast-feeding," she said.

French said another possibility for the difference seen in valproate exposure in utero versus during breast-feeding may be that "the brain is developing incredibly rapidly in utero, and so that may be a very sensitive time for exposure to valproate."

Meador cautioned that the results were preliminary and that additional studies covering a wider range of antiepilepsy drugs are needed.

"We studied the four most commonly used drugs in our epilepsy centers during the time the women were enrolled," he said. "We're now hoping to get additional funding to go and look at other drugs."

The study was funded by the U.S. National Institutes of Health and the U.K. Epilepsy Research Foundation.

More information

There's more on epilepsy and pregnancy at the Epilepsy Foundation.

SOURCES: Kimford J. Meador, M.D., professor of neurology, Emory University, Atlanta; Autumn Klein, M.D., Ph.D., director, Program in Women's Neurology, Brigham and Women's Hospital, Boston; Jacqueline A. French, M.D., professor of neurology, New York University School of Medicine, NYU Langone Medical Center, New York City; Nov. 24, 2010, Neurology, online


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Company Invites Women to STOP PMS - Take the 10-Minute Challenge
2. LifestyleMom.com and the LifestyleMom Radio Cafe Aim to Help Women Create a Family Life and "Me Life" That They Truly Love
3. Women More Likely to Fail Treatment for Atrial Fibrillation
4. Diabetes drug ups risk for bone fractures in older women
5. Womens Heart Disease Awareness Still Lacking
6. Cyndi Lauper, Lady Gaga Put Spotlight on Women and HIV
7. American Heart Association Rapid Access Journal Report: Study Finds Racial Gaps Continue in Heart Disease Awareness, Low Knowledge of Heart Attack Warning Signs Among Women
8. Womens Dermatologic Society Marks 35th Anniversary with Release of Unprecedented Book of Wisdom and Inspiration
9. Few Women at High Risk for Breast Cancer Take Tamoxifen
10. Diane von Furstenberg Establishes The DVF Awards to Recognize Outstanding Women Leaders
11. YazTalk Warns Women of Life Threatening Side Effects
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Women Taking Certain Epilepsy Drugs Can Safely Breast-Feed, Study Suggests
(Date:6/27/2016)... , ... June 27, 2016 , ... ... , the only authorized OSHA Training Institute Education Center headquartered in Northern California, ... their workers from extreme heat at their worksites. Employers with workers exposed ...
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal ... Final Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. ... Cut Pro X users can now reveal the media of their split screens ...
(Date:6/27/2016)... ... ... TherapySites, the leading website and online marketing ... Association. This new relationship allows TherapySites to continue to extend their online ... and promotional offers. , "TCA is extremely excited about this new partnership, as ...
(Date:6/27/2016)... California (PRWEB) , ... June ... ... pioneer in the patient payment industry today announced its strategic partnership with ... health system workflows. , The two companies’ proven, proprietary technology combine to ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... technology to revolutionize the emergency ambulance transport experience for the millions of people ... how Uber has disrupted the taxi industry through the use of technology. Now, ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... Australia,s successful biotechnology scientists, Dr Graham ... Noxopharm Limited [ABN 50 608 966 123] ("Noxopharm"). Noxopharm is seeking ... ASX. Noxopharm is a clinic-ready company with its first ... study later this year. NOX66 ... cancer patients - the ability of cancers to become resistant to ...
(Date:6/26/2016)... -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) ... Improvements Act of 1976, as amended ("HSR"), with respect ... Nasdaq: CPXX ) expired effective June 24, ... As previously announced on May 31, 2016, Jazz Pharmaceuticals ... which Jazz Pharmaceuticals has commenced a tender offer for ...
(Date:6/26/2016)...  VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ) reported ... required to build a strong and stable market for ... on the OTC Markets-pink current trading platform. ... are seeing an anomaly in market trading activities that ... the Company, but shareholders and market players as well. ...
Breaking Medicine Technology: